Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 15 January 2006, Vol. 107, No. 2, pp. 661-668.
Prepublished online as a Blood First Edition Paper on October 4, 2005; DOI 10.1182/blood-2005-03-1186.


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2005-03-1186v1
107/2/661    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Arimura, A.
Right arrow Articles by Batuman, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arimura, A.
Right arrow Articles by Batuman, V.
Related Collections
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Next Article next article arrow

Submitted March 29, 2005
Accepted July 29, 2005

Potential protective action of pituitary adenylate cyclase-activating polypeptide (PACAP38) on in vitro and in vivo models of myeloma kidney injury

Akira Arimura*, Min Li, and Vecihi Batuman

US-Japan Biomedical Research Laboratories, Tulane University F. Edward Hebert Research Center, New Orleans, LA, USA; Department of Medicine, Tulane University School of Medicine, New Orleans, LA, USA
Department of Medicine, Tulane University School of Medicine, New Orleans, LA, USA

* Corresponding author; email: arimura{at}tulane.edu.

The most common type of renal injury in multiple myeloma is chronic tubulointerstitial nephropathy associated with casts in tubule lumens, an entity referred to as "myeloma kidney" that often progresses to end stage kidney diseases. Myeloma kidney is associated with a significant increase in all-cause mortality, yet no effective intervention, except a limited use of steroid, is available. Here, we report that PACAP38 dramatically prevents injury of cultured renal proximal tubule cells caused by myeloma light chains through suppression of proinflammatory cytokines production, by inhibiting p38 MAPK and translocation of NF{kappa}B via both PAC1- and VPAC1-receptors. The suppressive effects of PACAP was as effective as dexamethasone in all of their cytokine assays, and demonstrated both in vitro and in vivo. Furthermore, PACAP38 inhibits myeloma cell growth directly and may also indirectly by suppressing production of the growth factor, IL-6, from bone marrow stromal cells, that is stimulated by adhesion of myeloma cells. These findings render PACAP38 worth evaluation as a promising candidate for an effective and safe renoprotectant in myeloma kidney, and possibly other nephropathy, and also as a new antitumor agent in multiple myeloma.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article in Blood Online:

A new twist in myeloma treatment
Paul W. Sanders
Blood 2006 107: 413-414. [Full Text] [PDF]



This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
M. Li, K. S. Hering-Smith, E. E. Simon, and V. Batuman
Myeloma light chains induce epithelial-mesenchymal transition in human renal proximal tubule epithelial cells
Nephrol. Dial. Transplant., March 1, 2008; 23(3): 860 - 870.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
M. Hautmann, U. G. Friis, M. Desch, V. Todorov, H. Castrop, F. Segerer, C. Otto, G. Schutz, and F. Schweda
Pituitary Adenylate Cyclase-Activating Polypeptide Stimulates Renin Secretion via Activation of PAC1 Receptors
J. Am. Soc. Nephrol., April 1, 2007; 18(4): 1150 - 1156.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
P.-X. Wang and P. W. Sanders
Immunoglobulin Light Chains Generate Hydrogen Peroxide
J. Am. Soc. Nephrol., April 1, 2007; 18(4): 1239 - 1245.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Li, S. Cortez, T. Nakamachi, V. Batuman, and A. Arimura
Pituitary Adenylate Cyclase-Activating Polypeptide Is a Potent Inhibitor of the Growth of Light Chain-Secreting Human Multiple Myeloma Cells.
Cancer Res., September 1, 2006; 66(17): 8796 - 8803.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020